Login / Signup

Genomic and evolutionary classification of lung cancer in never smokers.

Tongwu ZhangPhilippe JoubertNaser Ansari-PourWei ZhaoPhuc H HoangRachel LokangaAaron L MoyeJennifer RosenbaumNuria Lopez-BigasFrancisco Martinez-JimenezAndrea CastroLucia Anna MuscarellaPaul HofmanDario ConsonniAngela Cecilia PesatoriMichael KebedeMengying LiBonnie E Gould RothbergIliana PenevaMatthew B SchabathMaria Luana PoetaManuela CostantiniDaniela HirschKerstin Heselmeyer-HaddadAmy HutchinsonMary OlanichScott M LawrencePetra LenzMáire A DugganPraphulla M S BhawsarJian SangJung KimLaura MendozaNatalie SainiLeszek J KlimczakS M Ashiqul IslamBurcak OtluAzhar KhandekarNathan ColeDouglas R StewartJiyeon ChoiKevin K BrownNeil E CaporasoSamuel H WilsonYves PommierQing LanNathaniel RothmanJonas S AlmeidaHannah CarterThomas RiedCarla F KimNúria López-BigasMontserrat Garcia-ClosasJianxin ShiYohan BosséBin ZhuDmitry A GordeninLudmil B AlexandrovStephen J ChanockDavid C WedgeMaria Teresa Landi
Published in: Nature genetics (2021)
Lung cancer in never smokers (LCINS) is a common cause of cancer mortality but its genomic landscape is poorly characterized. Here high-coverage whole-genome sequencing of 232 LCINS showed 3 subtypes defined by copy number aberrations. The dominant subtype (piano), which is rare in lung cancer in smokers, features somatic UBA1 mutations, germline AR variants and stem cell-like properties, including low mutational burden, high intratumor heterogeneity, long telomeres, frequent KRAS mutations and slow growth, as suggested by the occurrence of cancer drivers' progenitor cells many years before tumor diagnosis. The other subtypes are characterized by specific amplifications and EGFR mutations (mezzo-forte) and whole-genome doubling (forte). No strong tobacco smoking signatures were detected, even in cases with exposure to secondhand tobacco smoke. Genes within the receptor tyrosine kinase-Ras pathway had distinct impacts on survival; five genomic alterations independently doubled mortality. These findings create avenues for personalized treatment in LCINS.
Keyphrases